BioMarin Pharmaceutical Inc. (BMRN) Down 5.4% — Time to Sell and Move Forward?
BioMarin Pharmaceutical Inc. (BMRN) is ceding ground in Tuesday's session, last changing hands at $54.33 on the NASDAQ — a $3.11 decline from the prior close of $57.44. The selloff extends a retreat that has been building for nearly three months. BMRN now trades roughly 23.5% below its 52-week high of $70.98, a level the stock reached on August 12, 2026. Much of the optimism that carried shares to that peak over the summer has now unwound.
Volume stands at approximately 785,983 shares so far in the session, compared with a 90-day average of roughly 2.11 million. With the regular session still open, turnover is running at a little over a third of a typical full day.
Why BioMarin Pharmaceutical Inc. Price is Moving Lower
The quarter itself was not the problem. The selling stems from the weaker 2026 outlook BioMarin issued alongside its Q3 results on November 2. Revenue came in at $1.025 billion against a $989 million consensus, up 32% year over year, and non-GAAP EPS of $0.23 matched expectations. Management then cut its 2026 revenue forecast to $3.80 billion to $3.90 billion from $3.875 billion to $3.925 billion. It also lowered its non-GAAP EPS outlook sharply, to $2.80 to $3.10 from $4.90 to $5.10. The company attributed part of the revenue revision to uncertainty around roughly $70 million of orders from a single international customer, some of which could slip from late 2026 into early 2027. Management framed that as a timing issue rather than softer patient demand. The revised outlook also builds in lower forecasts for Voxzogo and the metabolic business, however, and that is harder to dismiss as a calendar quirk.
Most of the EPS reduction traces to deal costs. BioMarin estimated a combined $1.87-per-share hit from the Alesta acquisition and the BMN 450 license. Even with those charges stripped out, the implied EPS range of $4.67 to $4.97 sits below the $5.00 midpoint of prior guidance, so the core earnings picture has also softened. GAAP results moved further into the red, with a $123 million net loss compared with a $31 million loss a year earlier.
The decline stands out against a firmer Health Care tape. Moderna, Inc. (MRNA) is up 6.24% and Zoetis Inc. (ZTS) is up 0.38% in the same session, which points to a company-specific reaction rather than sector rotation. The FDA has set May 30, 2027 as its target decision date for Voxzogo in hypochondroplasia. That gives the stock a potential longer-term catalyst, but it does little to offset a guidance reset today.
What is the BioMarin Pharmaceutical Inc. Rating - Should I Sell?
Weiss Ratings assigns BMRN a D rating. Current recommendation is Sell. The rating reflects a company whose top line is expanding while its earnings power, shareholder returns, and price stability have not kept pace. This week's guidance cut sharpens that disconnect.
The clearest strength is the balance sheet. BioMarin is rated Excellent on the Solvency Index, meaning the company can fund the Alesta acquisition and the BMN 450 license without straining its financial position. For investors weighing a business that just absorbed $1.87 per share in deal-related charges, that flexibility is meaningful. The Efficiency Index is rated Fair, a step below. A 2.14% profit margin and a 1.18% ROE are thin results for a rare-disease franchise that commands premium pricing on its therapies. The non-GAAP figures suggest more underlying profitability than the GAAP numbers show, which helps explain why the rating is not lower. The widening GAAP loss in the third quarter shows why it is not higher.
Where the picture becomes more difficult is growth and shareholder experience. The Weak rating on the Growth Index may seem at odds with 19.91% revenue growth, but sales momentum has not translated into earnings momentum. EPS sits at just $0.37, and the latest outlook lowers both Voxzogo and metabolic-business expectations. The Total Return Index and the Volatility Index are also rated Weak. A stock trading about 23.5% below its August high has not rewarded holders. A 5.41% single-session drop on a guidance revision, on a day when sector peers moved higher, illustrates why the Volatility Index is not rated higher.
Within the Health Care sector, BioMarin sits alongside Zoetis Inc. (ZTS, D) and slightly behind IQVIA Holdings Inc. (IQV, D+). It ranks ahead of Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-). That ranking offers limited reassurance, since every name in this peer group carries a Sell recommendation.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) is a Health Care company that focuses on therapies for rare and often life-threatening genetic diseases. Headquartered in San Rafael, California, the company built its business on enzyme replacement therapies for inherited metabolic disorders. These include Vimizim for MPS IVA, Naglazyme for MPS VI, and Aldurazyme for MPS I, along with Brineura for CLN2 disease, a form of Batten disease. Its phenylketonuria franchise includes Kuvan and Palynziq, which address a lifelong metabolic condition affecting how patients process protein.
Voxzogo has become the company's most important growth driver. It is approved to increase linear growth in children with achondroplasia, the most common form of dwarfism. BioMarin is working to broaden its use, and the pending hypochondroplasia application is the next major step in that effort. The company is also adding to its pipeline through business development, including the Alesta acquisition and the BMN 450 license.
BioMarin's competitive position rests on deep expertise in small patient populations, where specialized manufacturing, regulatory experience, and long-term relationships with treating physicians create meaningful barriers to entry. Its global commercial footprint allows it to serve patients across many international markets. That reach also exposes the company to the lumpy ordering patterns from government and institutional buyers that surfaced in the latest outlook.
Investor Outlook
BioMarin Pharmaceutical Inc. (BMRN) carries a Weiss Rating of D (Sell). A lowered 2026 outlook and a widening GAAP loss argue for caution even as revenue continues to grow. Investors should watch whether the roughly $70 million in delayed international orders lands in early 2027 as management suggests, how Voxzogo demand trends against the reduced forecast, and the FDA's 2027 decision on hypochondroplasia. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--